Next Article in Journal
Complex DNA Damage: A Route to Radiation-Induced Genomic Instability and Carcinogenesis
Next Article in Special Issue
Most Do, but Some Do Not: CD4+CD25 T Cells, but Not CD4+CD25+ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
Previous Article in Journal
SIRT3: Oncogene and Tumor Suppressor in Cancer
Previous Article in Special Issue
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Cancers 2017, 9(7), 92; https://doi.org/10.3390/cancers9070092

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy

Department of Surgery, Boston University, Boston, MA 02118, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Received: 9 June 2017 / Revised: 8 July 2017 / Accepted: 11 July 2017 / Published: 18 July 2017
(This article belongs to the Special Issue CAR-T Cell Therapy against Different Types of Cancer)
View Full-Text   |   Download PDF [3408 KB, uploaded 18 July 2017]   |  

Abstract

Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use in solid tumors has been hampered by multiple obstacles. Several approaches have been taken to circumvent these obstacles, including the regional delivery of CAR-T cells. Regional CAR-T cell delivery can theoretically compensate for poor T-cell trafficking and tumor antigen specificity while avoiding systemic toxicity associated with intravenous delivery. We reviewed completed clinical trials for the treatment of glioblastoma and metastatic colorectal cancer and examined the data in these studies for safety, efficacy, and potential advantages that regional delivery may confer over systemic delivery. Our appraisal of the available literature revealed that regional delivery of CAR-T cells in both glioblastoma and hepatic colorectal metastases was generally well tolerated and efficacious in select instances. We propose that the regional delivery of CAR-T cells is an area of potential growth in the solid tumor immunotherapy, and look towards future clinical trials in head and neck cancer, mesothelioma, and peritoneal carcinomatosis as the use of this technique expands. View Full-Text
Keywords: Chimeric Antigen Receptor T-Cell delivery; CAR-T; regional CAR-T delivery; solid tumor immunotherapy Chimeric Antigen Receptor T-Cell delivery; CAR-T; regional CAR-T delivery; solid tumor immunotherapy
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sridhar, P.; Petrocca, F. Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy. Cancers 2017, 9, 92.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top